Hims & Hers health chief commercial officer sells $68,932 in stock

SAN FRANCISCO—Michael Chi, the Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock transactions, according to a recent SEC filing. On December 2, Chi sold 2,054 shares of the company's Class A Common Stock at a price of $33.56 per share, amounting to a total of $68,932.

The transactions were part of a pre-established Rule 10b5-1 trading plan adopted on March 1, 2024. In addition to the sale, Chi also exercised stock options to acquire 2,054 shares at a price of $11.53 per share, totaling $23,682. According to InvestingPro analysis, HIMS maintains a strong financial health score, with liquid assets exceeding short-term obligations and moderate debt levels.

Following these transactions, Chi holds 184,947 shares of Hims & Hers Health directly. The company's stock transactions and Chi's trading activities are closely watched by investors, as they often provide insights into executive sentiment regarding the company's future prospects.

In other recent news, Hims & Hers Health, Inc. reported a significant 77% year-over-year increase in third-quarter sales, surpassing $400 million, with an adjusted EBITDA over $50 million. The company projected Q4 2024 revenue between $465 million and $470 million, marking an 89% to 91% year-over-year increase. Full-year revenue is expected to be between $1.46 billion and $1.465 billion. The company also expanded its board of directors and appointed a new independent director, Deb Autor.

Analyst firms have weighed in on Hims & Hers' performance. BofA Securities maintained an Underperform rating on Hims & Hers due to Amazon (NASDAQ:AMZN)'s entry into key markets, while TD Cowen reaffirmed its Buy rating. Piper Sandler and Needham raised their price targets, maintaining Neutral and Buy ratings respectively.

Hims & Hers' future could be influenced by potential FDA leadership ties, as suggested by a report from Hunterbrook Media. The report indicates that the company could benefit from President-elect Donald Trump's nominee for the Food and Drug Administration (FDA) commissioner, Dr. Martin Makary, currently an executive at Sesame, a telehealth company that, like Hims & Hers, sells compounded GLP-1 drugs online.

Finally, Hims & Hers announced plans to launch liraglutide, the first generic GLP-1, in 2025. These are the recent developments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.